PDF factsheet
      Z

antiplatelets drug in cardiovascular prevention for secondary prevention in patients with CAD, clinical trials results

aspirin versus placebo
CDPA, 1976
Aspirin (324 mg) 3x/d
versus
Placebo
MI survivorsDouble blind
Follow-up duration: 1.83 y
USA
Cardiff I, 1974
Aspirin (300 mg) 1x/d
versus
Placebo
MI survivorsDouble blind
Follow-up duration: 2 years
UK
Cardiff II, 1979
Aspirin (300 mg) 3x/d for one year
versus
Placebo
patients with myocardial infarctionDouble blind
Follow-up duration: 1 y
South Wales
Vogel, 1979
Aspirin (1.5 g daily) on an average period of 22 months
versus
Placebo
Double blind
Follow-up duration: 1.75 y (mean)
Germany
AMIS, 1980
NCT00000491
Aspirin (500 mg) 2x/d for at least 3 years
versus
Placebo
men and women who had had a documented myocardial infarctionDouble blind
Follow-up duration: > 3 y
USA
GAMIS, 1980
Aspirin (500 mg) 3x/d for 2 years
versus
Placebo
patients who had survived a myocardial infarction for 30-42 days Double blind
Follow-up duration: 2 y
Germany, Austria,
PARIS, 1980
Aspirin (324 mg) 3x/d
versus
Placebo
patients who had recovered from myocardial infarction Double blind
Follow-up duration: 41 mo
USA, UK
JAMIS, 1999
Aspirin (81 mg) 1x/d
versus
No antiplatelets
patients with AMI within 1 month from the onset of symptomsOpen
Follow-up duration: 1.3 y (mean)
Japan
SAPAT, 1992
aspirin 75 mg daily
versus
placebo
patients with stable chronic angina pectorisdouble blind
Follow-up duration: 50 months
Sweden
clopidogrel versus aspirin
ASCET,
NCT00222261
clopidogrel 75 mg once daily for two years
versus
Aspirin 160 mg once daily for two years
patients with documented coronary heart disease and treated with aspirinopen
CAPRIE, 1996
clopidogrel 75 mg once daily
versus
aspirin 325 mg once daily
patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial diseaseDouble blind
Follow-up duration: mean 1.91 years
16 countries
clopidogrel versus placebo (on top aspirin)
CHARISMA, 2006
NCT00050817
clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day)
versus
placebo plus low-dose aspirin
patients with either clinically evident cardiovascular disease or multiple risk factorsDouble blind
Follow-up duration: median 28 months
32 countries
dipyridamol versus control
Atlanta (Sbar), 1967
dipyridamole 150mg daily
versus
placebo
patients with angina pectorisdouble-blind
Follow-up duration: 6 months
Wirecki, 1967
dipyridamole 150mg daily
versus
placebo
patients with angina pectorisdouble blind
Follow-up duration: 7 months
Becker, 1967
dipyridamole 225mg daily
versus
placebo
double-blind
Follow-up duration: 5 months
dipyridamol versus placebo
Kinsella, 1962
dipyridamole 37.5 mg and 100mg daily
versus
placebo
double-blind
Follow-up duration: 0.5 months
Leiberman, 1964
dipyridamole 100mg daily
versus
placebo
double blind
Follow-up duration: >3 months
Zion, 1961
Dipyridamole 37.5mg
versus
placebo
patients with angina pectorisdouble-blind
Follow-up duration: 0.5 months
Dewar, 1961
Dipyridamole 100mg daily
versus
placebo
patients with angina pectorisdouble-blind
Follow-up duration: 0.5 months
Neumann, 1964
dipyridamole 150mg daily
versus
placebo
elderly with precordial paindouble-blind
Follow-up duration: 1.5 months
Foulds, 1960
Dipyridamole 200mg daily
versus
placebo
patients with angina pectorisdouble-blind
Follow-up duration: 1 months
Igloe, 1970
Dipyridamole 200mg daily
versus
placebo
patients with angina pectorisdouble blind
Follow-up duration: 2-7 months
dipyridamol + aspirin versus aspirin
PARIS, 1980
Aspirin (324 mg) + dipyridamole (75 mg) 3x/d
versus
Aspirin (324 mg) 3x/d
patuents who had recovered from myocardial infarction Double blind
Follow-up duration: 41 months
USA and GB
dipyridamol + aspirin versus placebo
PARIS, 1980
Aspirin (324 mg) + dipyridamole (75 mg) 3x/d
versus
Placebo
patients who had recovered from myocardial infarction Double blind
Follow-up duration: 41 months (mean)
USA and UK
PARIS-II, 1986
Aspirin (330 mg) + dipyridamole (75 mg) 3x/d
versus
Placebo
patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previouslyDouble blind
Follow-up duration: 23.4 months
USA and UK
ticagrelor versus placebo (on top aspirin)
PEGASUS 60mg, 2015
NCT01225562
ticagrelor at a dose of 60 mg twice daily
versus
placebo
patients who had had a myocardial infarction 1 to 3 years earlierdouble-blind
Follow-up duration: 2.75 y (median)
PEGASUS 90mg, 2015
NCT01225562
ticagrelor at a dose of 90 mg twice daily
versus
patients who had had a myocardial infarction 1 to 3 years earlier double-blind
Follow-up duration: 2.75 y (median)
ticlopidine versus placebo
Berglund, 1985
ticlopidine 500 mg daily
versus
placebo
middle-aged men with stable incapacitating angina pectorisdouble blind
Follow-up duration: 2m
vorapaxar versus placebo (on top aspirin)
TRA-2P TIMI 50, 2012
NCT00526474
vorapaxar (SCH 530348) 2.5-mg daily
versus
placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel)
patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease)double-blind
Follow-up duration: 2.5 y (median)

  Options


in first

in second

  Filter